Forge Biologics News and Resources

Affinia Therapeutics and Forge Biologics have announced a partnership to transfer technology and produce clinical trial material for Affinia’s gene therapy programs under Current Good Manufacturing Practice (cGMP) standards. The agreement covers Affinia’s investigational treatment AFTX-201, developed to target BAG3

Forge Biologics has introduced its new FUEL (Foundation for Unleashing Excellence in Life-Changing Therapies) manufacturing platform, aimed at providing AAV gene therapy developers with a faster and more efficient process for advancing their therapeutic programs. The platform’s launch includes technical

Forge Biologics, a manufacturer of genetic medicines and part of the Ajinomoto Biopharma Services group, has announced a leadership change. Timothy J. Miller, Ph.D., will step down from his role as Chief Executive Officer after nearly five years. John Maslowski,

Forge Biologics, a gene therapy CDMO, has been selected as the adeno-associated virus (AAV) manufacturing partner for the Muscular Dystrophy Association’s (MDA) Kickstart Program. This initiative, created by the MDA, aims to lower commercial barriers and facilitate the development of